Abstract LSUHSC CARC Alzheimer’s Disease Supplement NOT-AG-22-025
At-risk alcohol use is frequently co-morbid with HIV and may exacerbate the development of Alzheimer’s
disease (AD)-related risk factors in persons living with HIV (PLWH). Importantly, at-risk alcohol use may
synergize with additional co-morbid factors of increased age, frailty syndrome, low education and
socioeconomic status, metabolic comorbidities, physical inactivity, pain, and cognitive dysfunction to further
heighten the risk of progression to AD. Even in the post-antiretroviral therapy (ART) era, cognitive deficits
remain widespread in PLWH and as PLWH age, the risk of advanced stage dementias such as AD may
increase. However, the association of at-risk alcohol use with the presence of multi-morbid AD risk factors in
PLWH has not been thoroughly examined. Our longitudinal New Orleans Alcohol and HIV (NOAH) study of
PLWH and seronegative subjects provides an ideal platform to examine how alcohol interacts with multiple
organ systems and salient behaviors to promote AD risk. The studies proposed in this supplement build upon
our existing comprehensive research focus of understanding the integrative impact of environmental and
personal factors on at-risk alcohol use in PLWH and how these interactions promote relevant comorbidities
including frailty, pain, cognitive decline, and metabolic dyshomeostasis. Published and preliminary data from
our center demonstrate that PLWH exhibiting at-risk alcohol use display a greater frequency of immune
activation and senescence, frailty syndrome, metabolic dyshomeostasis, and cognitive impairment. Based on
its profound reactivity to key environmental and personal lifestyle factors and ability to influence the physiology
of multiple organ systems, the gut microbiota may represent a key nexus bridging multiple pathophysiological
processes linking at-risk alcohol use to AD risk factors in PLWH. For this P60 administrative supplement to the
Clinical and Experimental Core, our overarching hypothesis is that the gut microbiota circulating metabolome
profile is associated with increased risk factors for AD in PLWH. The proposed analysis will establish the
metabolome profiles associated with frailty, cognitive decline, pain symptoms, and metabolic dysregulation in
PLWH. In addition, we propose to identify the key modifying personal lifestyle factors for these associations
(i.e., at-risk alcohol and nicotine use, diet, and physical activity). We also propose to identify candidate
gastrointestinal microbiota characteristics and specific metabolites that can beeffectively targeted for the
development of novel therapeutic agents for ameliorating risk for AD in PLWH displaying at-risk alcohol use.
Importantly, this supplement closely aligns with studies in the parent P60 grant investigating the intersection of
alcohol and HIV pathophysiology and their impact on the most relevant comorbid conditions affecting quality of
life and healthy aging in PLWH.
Public Health Relevance Statement
Narrative LSUHSC CARC Alzheimer’s Disease Supplement NOT-AG-22-025
At-risk alcohol use is frequently co-morbid with HIV and may exacerbate the development of Alzheimer’s
disease-related risk factors in persons living with HIV. This administrative supplement to the Clinical and
Experimental Core of the NIAAA funded P60AA009803 will identify the gut microbiota related circulating
metabolome profile associated with increased risk factors for Alzheimer’s disease such as frailty, cognitive
decline, pain symptoms, and metabolic dysregulation in PLWH. This supplement closely aligns with studies in
the parent P60 grant investigating the intersection of alcohol and HIV pathophysiology on comorbid conditions
affecting quality of life and healthy aging in PLWH.
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
782627814
UEI
M7KCJ79FAVH5
Project Start Date
01-December-1996
Project End Date
30-November-2024
Budget Start Date
05-April-2023
Budget End Date
30-November-2023
Project Funding Information for 2023
Total Funding
$249,949
Direct Costs
$196,558
Indirect Costs
$53,391
Year
Funding IC
FY Total Cost by IC
2023
National Institute on Aging
$249,949
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P60AA009803-30S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P60AA009803-30S1
Patents
No Patents information available for 3P60AA009803-30S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P60AA009803-30S1
Clinical Studies
No Clinical Studies information available for 3P60AA009803-30S1
News and More
Related News Releases
No news release information available for 3P60AA009803-30S1
History
No Historical information available for 3P60AA009803-30S1
Similar Projects
No Similar Projects information available for 3P60AA009803-30S1